Aegera Therapeutics, Inc.
http://www.aegera.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aegera Therapeutics, Inc.
Novo Pumps Up Heart Failure Prospects With Cardior Purchase
The Danish drugmaker is spending some of its semaglutide cash on a mid-stage RNA-based heart failure therapy developed by the German biotech.
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Updated: Boston Scientific Buys Axonics For $3.4BN; Adds Neuromodulation To Incontinence Lineup
Analysts support Boston Scientific's plan to buy Axonics for $3.4bn in cash. The deal is expensive, but gives Boston Scientific a strong position in the fast-growing sacral neuromodulation (SNM) therapy market and boosts its existing portfolio of products for incontinence.
News We’re Watching: Apple/Masimo Patent Fight Update; Acutus Winds Down; Illumina Bails On Grail
Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. In addition to the big news from Acutus, Apple, and Illumina, Masimo scored an important FDA clearance, Beta Bionics announced the US launch of its iLet bionic pancreas for Dexcom’s G7 CGM, and more.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice